Literature DB >> 30644987

Evaluation and Management of Penicillin Allergy: A Review.

Erica S Shenoy1,2,3, Eric Macy4, Theresa Rowe5, Kimberly G Blumenthal1,6,7.   

Abstract

IMPORTANCE: β-Lactam antibiotics are among the safest and most effective antibiotics. Many patients report allergies to these drugs that limit their use, resulting in the use of broad-spectrum antibiotics that increase the risk for antimicrobial resistance and adverse events. OBSERVATIONS: Approximately 10% of the US population has reported allergies to the β-lactam agent penicillin, with higher rates reported by older and hospitalized patients. Although many patients report that they are allergic to penicillin, clinically significant IgE-mediated or T lymphocyte-mediated penicillin hypersensitivity is uncommon (<5%). Currently, the rate of IgE-mediated penicillin allergies is decreasing, potentially due to a decreased use of parenteral penicillins, and because severe anaphylactic reactions to oral amoxicillin are rare. IgE-mediated penicillin allergy wanes over time, with 80% of patients becoming tolerant after a decade. Cross-reactivity between penicillin and cephalosporin drugs occurs in about 2% of cases, less than the 8% reported previously. Some patients have a medical history that suggests they are at a low risk for developing an allergic reaction to penicillin. Low-risk histories include patients having isolated nonallergic symptoms, such as gastrointestinal symptoms, or patients solely with a family history of a penicillin allergy, symptoms of pruritus without rash, or remote (>10 years) unknown reactions without features suggestive of an IgE-mediated reaction. A moderate-risk history includes urticaria or other pruritic rashes and reactions with features of IgE-mediated reactions. A high-risk history includes patients who have had anaphylaxis, positive penicillin skin testing, recurrent penicillin reactions, or hypersensitivities to multiple β-lactam antibiotics. The goals of antimicrobial stewardship are undermined when reported allergy to penicillin leads to the use of broad-spectrum antibiotics that increase the risk for antimicrobial resistance, including increased risk of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Broad-spectrum antimicrobial agents also increase the risk of developing Clostridium difficile (also known as Clostridioides difficile) infection. Direct amoxicillin challenge is appropriate for patients with low-risk allergy histories. Moderate-risk patients can be evaluated with penicillin skin testing, which carries a negative predictive value that exceeds 95% and approaches 100% when combined with amoxicillin challenge. Clinicians performing penicillin allergy evaluation need to identify what methods are supported by their available resources. CONCLUSIONS AND RELEVANCE: Many patients report they are allergic to penicillin but few have clinically significant reactions. Evaluation of penicillin allergy before deciding not to use penicillin or other β-lactam antibiotics is an important tool for antimicrobial stewardship.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30644987     DOI: 10.1001/jama.2018.19283

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  89 in total

1.  Penicillin Allergy Evaluation Access: A National Survey.

Authors:  Christian M Mancini; Xiaoqing Fu; Yuqing Zhang; Kristi Kuper; Lucas T Schulz; Tanaya Bhowmick; Michael Postelnick; Francesca Lee; Rochelle P Walensky; Kimberly G Blumenthal
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

2.  Considerations for Designing EHR-Embedded Clinical Decision Support Systems for Antimicrobial Stewardship in Pediatric Emergency Departments.

Authors:  Mustafa Ozkaynak; Noel Metcalf; Daniel M Cohen; Larissa S May; Peter S Dayan; Rakesh D Mistry
Journal:  Appl Clin Inform       Date:  2020-09-09       Impact factor: 2.342

3.  High-cost, high-need patients: the impact of reported penicillin allergy.

Authors:  Kimberly G Blumenthal; Nicolas M Oreskovic; Xiaoqing Fu; Fatma M Shebl; Christian M Mancini; Jennifer M Maniates; Rochelle P Walensky
Journal:  Am J Manag Care       Date:  2020-04       Impact factor: 2.229

4.  Standardization and Updating of a Drug Allergy Testing Program: The McGill Experience and Impact on Pharmacy Activities.

Authors:  Gilbert Matte; Joseph Shuster; Chantal Guevremont; Phil Gold; Fabrice Leong; Zinquon Ngan; André Bonnici; Chris Tsoukas
Journal:  Can J Hosp Pharm       Date:  2020-02-01

5.  Risk-stratified Management to Remove Low-Risk Penicillin Allergy Labels in the ICU.

Authors:  Cosby A Stone; Joanna L Stollings; Christopher J Lindsell; Mary Lynn Dear; Reagan B Buie; Todd W Rice; Elizabeth J Phillips
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

6.  Safety and efficacy of direct two-step penicillin challenges with an inpatient pharmacist-driven allergy evaluation.

Authors:  YoungYoon Ham; Ellie S Sukerman; James S Lewis; Kendall J Tucker; Diana L Yu; Shyam R Joshi
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

7.  Penicillin Allergy Delabeling: A Multidisciplinary Opportunity.

Authors:  Mary L Staicu; David Vyles; Erica S Shenoy; Cosby A Stone; Taylor Banks; Kristin S Alvarez; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 8.  Skin Testing for Penicillin Allergy: a Review of the Literature.

Authors:  Tracy Zembles; Michelle Mitchell; Waleed Alqurashi; Mariana Castells; Elizabeth J Phillips; David Vyles
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-18       Impact factor: 4.806

9.  Risk-based pathway for outpatient penicillin allergy evaluations.

Authors:  Kimberly G Blumenthal; Emily M Huebner; Xiaoqing Fu; Yu Li; Gita Bhattacharya; Amy S Levin; Christian M Mancini; Benjamin R Slawski; Aleena Banerji
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-11

Review 10.  Achieving the Quadruple Aim to deliver value-based allergy care in an ever-evolving health care system.

Authors:  Edward G A Iglesia; Matthew Greenhawt; Marcus S Shaker
Journal:  Ann Allergy Asthma Immunol       Date:  2020-04-11       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.